Identifying Novel Candidates for Re-Purposing as Potential Therapeutic Agents for Alzheimer's disease

The current paper describes the identification of novel candidate compounds for repositioning as treatments for Alzheimer9s disease (AD) from the CMAP library. Candidate compounds were identified based on inverse correlation with transcriptome signatures developed from meta-analyses of Alzheimer RNA expression studies using the SPIED platform. The 78 compounds with a significant inverse correlation were taken forward into an in vitro programme using 6 well validated screening assays relevant to potential treatment targets in AD. Nineteen of the compounds were hits in at least 2 of these assays. A description of each of these compounds is presented.